Literature DB >> 3542843

Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma.

C Caron de Fromentel, F May-Levin, H Mouriesse, J Lemerle, K Chandrasekaran, P May.   

Abstract

Serum samples taken from children bearing a wide variety of tumors were screened for the presence of circulating antibodies against the cellular tumor antigen p53. There was a significant correlation (p less than 0.001, n = 119) between the presence of such antibodies and the occurrence of cancer; 12% of the sera tested were positive. These sera were derived from children with a wide range of tumor types. In particular, 21% of the sera obtained from children suffering from a B-cell lymphoma contained anti-p53 antibodies. We were not able to establish a correlation between the secretion of p53-reactive antibodies and any other parameters, such as the age or sex of the child, presence of metastasis, stage or prognosis of disease, or treatment regimen. These results therefore show that the development of p53 immunogenicity is associated with a wide range of neoplastic diseases in children, and in particular with the presence of a B-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3542843     DOI: 10.1002/ijc.2910390211

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

Review 1.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

2.  Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.

Authors:  P Hammel; B Boissier; M T Chaumette; P Piedbois; N Rotman; J C Kouyoumdjian; R Lubin; J C Delchier; T Soussi
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

3.  Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.

Authors:  Keiji Shimizu; Yuji Ueda; Hisakazu Yamagishi
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

Review 4.  p53: twenty five years understanding the mechanism of genome protection.

Authors:  M Gomez-Lazaro; F J Fernandez-Gomez; J Jordán
Journal:  J Physiol Biochem       Date:  2004-12       Impact factor: 4.158

5.  Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma.

Authors:  Y Z Zhou; B L Slagle; L A Donehower; P vanTuinen; D H Ledbetter; J S Butel
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

6.  Evolutionary conservation of the biochemical properties of p53: specific interaction of Xenopus laevis p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70.

Authors:  T Soussi; C Caron de Fromentel; H W Stürzbecher; S Ullrich; J Jenkins; P May
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.

Authors:  Mary L Disis; Vivian Goodell; Kathy Schiffman; Keith L Knutson
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

8.  Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.

Authors:  P Laurent-Puig; R Lubin; S Semhoun-Ducloux; G Pelletier; C Fourre; M Ducreux; M J Briantais; C Buffet; T Soussi
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

9.  Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells.

Authors:  Marc R Theoret; Cyrille J Cohen; Azam V Nahvi; Lien T Ngo; Kimberly B Suri; Daniel J Powell; Mark E Dudley; Richard A Morgan; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2008-11       Impact factor: 5.695

10.  p53 antibodies in the serum of patients with prostate cancer.

Authors:  Yoko Kubota; Yoshiki Onmura; Hiroshi Ohji; Takuya Kunii; Tomohiro Shibasaki; Teruhiro Nakada; Yoshihiko Tomita
Journal:  Int Urol Nephrol       Date:  2007-07-06       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.